text:
Virtual FAQs
BlueRock Therapeutics Ballroom
COGNATE BALLROOM WEBCASTAVIARA SALON A WEBCAST AVIARA SALON B WEBCAST
BLUEROCK THERAPEUTICS BALLROOM LIVESTREAM AGENDA
WELCOME REMARKS {BlueRock Therapeutics Ballroom}
Janet Lambert, CEO, Alliance for Regenerative Medicine (ARM)
PLENARY SESSION: THE CELL AND GENE THERAPY SECTOR'S COMMERCIAL TRAILBLAZERS {BlueRock Therapeutics Ballroom}
Being first isn't always easy. Hear from the sector's pioneers as they share valuable lessons learned along the path to commercialization and discuss the outlook for the coming year.
Matthew Patterson, Chairman and CEO, Audentes Therapeutics
Vijay Chiruvolu, Ph.D., SVP, Global Process Development – Cell Therapy, Kite, a Gilead company
Rachelle Jacques, CEO, Enzyvant
David Lennon, Ph.D., President, AveXis
Ron Philip, Chief Commercial Officer, Spark Therapeutics
Jeff Walsh, Chief Strategy Officer, bluebird bio
10:15am – 10:45am | MORNING BREAK – NO LIVESTREAM AT THIS TIME
10:45am – 12:00pm | LIVESTREAM RESUMES
FEATURED FIRESIDE CHAT: BREXIT'S EFFECT ON CELL AND GENE THERAPY REGULATION {BlueRock Therapeutics Ballroom}
Jacqueline Barry, Ph.D., Chief Clinical Officer, Cell and Gene Therapy Catapult
Christiane Niederlaender, Ph.D., Director, AMBR-Consulting; Former Senior Quality Assessor for Biologics, Medicines and Healthcare Products Regulatory Agency (MHRA); Former Member, Committee for Advanced Therapies (CAT), European Medicines Agency (EMA)
COMPANY PRESENTATIONS {BlueRock Therapeutics Ballroom}
bluebird bio
Gamida Cell
12:00pm – 1:15pm | LUNCH – NO LIVESTREAM AT THIS TIME
1:15pm – 3:30pm | LIVESTREAM RESUMES
PANEL: MYTH VS. REALITY – IMPLEMENTING PAYMENT ARRANGEMENTS FOR CELL AND GENE THERAPIES {BlueRock Therapeutics Ballroom}
Payers and therapeutic developers are starting to implement payment-over-time and pay-for-performance arrangements. Where does the reality on the ground diverge from common perception? What role are third parties playing today and what needs to change in order for these arrangements to be widespread?
Roger Longman, Founder and Chairman, Real Endpoints
John Coombs, Pharm.D., Patient Access Lead, U.S. CAR-T, Novartis
C. Bernie Good, M.D., Senior Medical Director, Center for Value-Based Pharmacy Initiatives, UPMC Health Plan
Bill Martin, VP, Pharma Strategy and Account Management, Express Scripts
Homology Medicines
Flexion Therapeutics
uniQure
REGENXBIO
Sangamo Therapeutics
3:30pm – 4:00pm | AFTERNOON BREAK – NO LIVESTREAM AT THIS TIME
4:00pm – 6:00pm | CONCURRENT TRACKS – LIVESTREAM RESUMES
PANEL: CELL AND GENE THERAPY FOR NEUROLOGICAL PRODUCT INDICATIONS {BlueRock Therapeutics Ballroom}
Durable treatments for the complex range of diseases affecting the central nervous system have long been an area of focus for the medical community. With advances in gene and cell therapy, there is a growing range of therapeutic strategies which may provide long awaited relief to myriad patient populations. This panel will review the state of development and clinical progress for these next-generation durable treatments for CNS conditions.
Timothy Schroeder, Founder and CEO, CTI Clinical Trial & Consulting
Jonathan Garen, Chief Business Officer, uniQure
Emile Nuwaysir, Ph.D., President and CEO, BlueRock Therapeutics
Andre Turenne, President and CEO, Voyager Therapeutics
David Venables, Ph.D., CEO, Synpromics
Orchard Therapeutics
Oxford Biomedica
AVROBIO
LogicBio
6:00pm | LIVESTREAM ENDS FOR THE DAY
OVERVIEW OF THE ALLIANCE FOR REGENERATIVE MEDICINE'S INITIATIVES {BlueRock Therapeutics Ballroom}
Matthew Patterson, Chairman, Alliance for Regenerative Medicine (ARM); Chairman and CEO, Audentes Therapeutics
PANEL: CLINICIANS WORKING WITH CAR-T THERAPIES {BlueRock Therapeutics Ballroom}
Thousands of patients have now been treated with CAR-T therapies. Find out what unique challenges and rewards come with providing these treatments from those on the front lines, and learn what the experience to date suggests about the widespread use of CAR-T.
Gregory Hale, M.D., Senior Medical Director, Hematology and Oncology, Medpace
Prasad S. Adusumilli, M.D., Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center; Vice Chair, Department of Surgery; Deputy Chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center
Dimitrios Tzachanis, M.D., Ph.D., Associate Clinical Professor of Medicine, UC San Diego Blood and Marrow Transplant Program
John A. Zaia, M.D., Aaron D. Miller and Edith Miller Chair in Gene Therapy; Director, Center for Gene Therapy, City of Hope
FEATURED SPEAKER: ADVANCING GENE THERAPIES GREAT AND SMALL {BlueRock Therapeutics Ballroom}
Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
PANEL: WHEN DOES INVESTING IN CELL AND GENE THERAPY MAKE BUSINESS SENSE? {BlueRock Therapeutics Ballroom}
The cell and gene therapy industry is undergoing a critical inflection point as is evident in large financing deals, exciting clinical data and landmark regulatory approvals. However assets also face challenges such as high development costs and significant manufacturing complexities. Through a presentation and panel discussion, this session will define drivers of cost of development and cost of goods and provide a framework for assessing investment potential of cell and gene therapy assets.
Delfi Krishna, Ph.D., Director, Cell and Gene Therapy Platform, R&D Strategy, Portfolio and Operations, GSK
Brian Bronk, Ph.D., Head of Business Development, Rare Diseases and Blood Disorders, Global Business Development and Licensing, Sanofi
Bradley Campbell, President and Chief Operating Officer, Amicus Therapeutics
Jerel Davis, Ph.D., Managing Director, Versant Ventures
Mitchell Finer, Ph.D., Chief Scientific Officer, ElevateBio; President, ElevateBio Base Camp
Toby Freyman, Ph.D., Senior Director, Center for External Innovation; Head of Rare Disease Business Development, Takeda Pharmaceuticals International
SPOTLIGHT SESSION: THE EVOLUTION OF CELL AND GENE THERAPY IN CHINA {BlueRock Therapeutics Ballroom}
Senior executives active in the region will share their experience and outlook on the cell and gene therapy industry in China, with advice for those considering expansion or are new to the market.
Li Chen, Ph.D., VP, Gene Synthesis and Mol LCS, BID, LSG, Thermo Fisher Scientific
Felix Hsu, SVP and Global Head of Advanced Therapies, WuXi AppTec
Yuling Li, Ph. D., CEO, Zhejiang Innoforce Pharmaceuticals Co. Ltd.
BG Rhee, Ph.D., CEO, SCM Lifescience; Chairman, Council for Advanced Regenerative Medicine (CARM) Korea
Amicus Therapeutics
Adaptimmune
Autolus
PANEL: THE IMPACT OF UNIVERSAL DONOR CELLS AND iPSCs ON THE CELL THERAPY INDUSTRY {BlueRock Therapeutics Ballroom}
Since the discovery of pluripotent stem cells in the early 1980's, the promise of fit-to-purpose cell replacement therapy has occupied the imaginations of many in the medical and patient communities. Progress was slowed by both technical and ethical challenges, but with the discovery of the iPSC source in 2006, many of these hurdles were overcome and the pace of research and clinical development accelerated dramatically. Further, genetic and biomaterials modification to this limitless supply of cells has opened new doors to allogeneic stem cell-derived cell therapy, including the associated promise of lower costs and higher accessibility. This panel will explore the ways in which iPSCs, and more specifically iPSCs modified for allogeneic use, have changed the way in which we think about the commercial viability of cell therapies.
Robert Preti, Ph.D., President and CEO, Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector
Stewart Abbot, Ph.D., Chief Operating and Scientific Officer, Adicet Bio
Usman Azam, M.D., President and CEO, Tmunity Therapeutics
Tim Lu, M.D., Ph.D., Co-Founder and CEO, Senti Biosciences
Bastiano Sanna, Ph.D., CEO, Semma Therapeutics
Dan Shoemaker, Ph.D., Chief Scientific Officer, Fate Therapeutics
Precision BioSciences
Axovant Gene Therapies
Magenta Therapeutics
Lineage Cell Therapeutics
Fate Therapeutics
Iovance Biotherapeutics
Athersys
9:00am | GENERAL SESSION OPENS – LIVESTREAM BEGINS
OVERVIEW OF THE ARM FOUNDATION FOR CELL AND GENE MEDICINE {BlueRock Therapeutics Ballroom}
Morrie Ruffin, Co-Founder and Senior Advisor, Alliance for Regenerative Medicine; Executive Director, ARM Foundation for Cell and Gene Medicine
Stewart Parker, Chairperson, ARM Foundation for Cell and Gene Medicine
FEATURED SPEAKERS: EMILY WHITEHEAD'S JOURNEY TO CAR-T – NO LIVESTREAM AT THIS TIME {BlueRock Therapeutics Ballroom}
Emily Whitehead, Co-Founder, Emily Whitehead Foundation
Tom Whitehead, Co-Founder, Emily Whitehead Foundation
PANEL: A LOOK INTO THE CRYSTAL BALL – WHAT DOES THE FUTURE HOLD FOR GENE EDITING? {BlueRock Therapeutics Ballroom}
This dynamic panel discussion featuring executives from leading gene editing companies will explore the major milestones and advances anticipated in the near term (12 month), midterm (5 year), and long term (10+ year) timeframes for these promising therapies. This session will also consider how the rapidly evolving climate surrounding these technologies will potentially impact the future of the sector's success.
Robert Smith, SVP, Global Gene Therapy Business, Pfizer
Cindy Collins, President and CEO, Editas Medicine
Michael Dombeck, SVP, Corporate Development, Precision BioSciences
Sandy Macrae, Ph.D., President and CEO, Sangamo Therapeutics
Arthur Tzianabos, Ph.D., President and CEO, Homology Medicines
PANEL: INNOVATION AROUND MANUFACTURING TECHNOLOGIES {BlueRock Therapeutics Ballroom}
In biotechnology, a good idea born in a lab too often fails to make it to clinical and commercial reality due to challenges in scalability, production, and characterization. For cell, gene, and tissue engineered products these challenges are particularly acute. It has even reached the point in which investors have begun seek a scalable platform over a promising idea. This panel will explore the next-generation technologies enabling the scalable, transferable, and cost-effective manufacture of regenerative medicine products and discuss the ways in which the regenerative medicine industry must continue to develop fit-for-purpose platforms to address sector specific CMC challenges.
Kelvin Lee, Ph.D., Institute Director, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Nina Bauer, Ph.D., Chief Commercial Officer, FloDesign Sonics
Jian Irish, Ph.D., SVP, Global Head of Manufacturing, Kite, a Gilead company
Jerry Keybl, Ph.D., Head of Cell and Gene Therapy Manufacturing, MilliporeSigma
Alberto Santagostino, Head, Cell and Gene Technologies Business Unit, Lonza Pharma & Biotech
Jason Slingsby, Ph.D., Chief Business Officer, Oxford Biomedica
12:00pm | LIVESTREAM ENDS
The Cell & Gene Meeting on the Mesa is the sector's foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 80+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,200 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 3,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.
Program Organizer
©2021 Cell & Gene Meeting on the Mesa · Site Developed by Tyler Clemmer
By using this website you agree to accept our Privacy Policy and Terms & Conditions


If you want tables since you run an industrial bar, the very best tables for your demands will certainly differ from a person who is interested in bar table collections for home use. Two essential features are essential to a commercially oriented bar: earnings making and resilience of the bar furnishings. A house bar will certainly not truly want earnings and also therefore, not truly be worried regarding cost cutting methods. An additional relevant point is the variety of bar furnishings being acquired. This will definitely be much more for an industrial pub. Kitchen Bar Table.
So, take the above points right into factor to consider along with the complying with points: readily available room, called for dimension of tables, budget plan, preferred design and make of the tables. Taking these actions will certainly assist you develop the very best tables for your demands. Kitchen Bar Table.


The Middlebury women's basketball team saw its successful season come to a close, as the Panthers fell to host DeSales 70-55 in the second round of the NCAA Tournament on Saturday. Middlebury capped the year with a record of 20-8, posting the most wins in a season since the 2001-02 campaign and the program's fifth 20-win season.
The 10th-ranked Bulldogs (27-2) extended their winning streak to 22-straight games, heading to next weekend's round of 16.
Middlebury opened the scoring with Betsy Knox sinking a jumper and Alex Huffman followed with a free throw for a 3-0 lead. The Panthers later got a conventional three-point play from Colleen Caveney with 4:56 left in the frame for a 9-7 edge, but the hosts finished on a 14-2 run for a 21-10 advantage after 10 minutes of play.
After the hosts went up 23-10 on a jumper by Bridget Walsh early in the second stanza, Middlebury used the free-throw line to close the gap. Knox made three straight from the charity stripe, while Caveney hit two more to make it a 23-15 score with 7:51 on the clock. Maya Davis tacked on two more from the line, capping a 7-0 run with all the points coming from the charity stripe. DeSales extended the lead to 36-22 on a layup by Samantha Shinkus with 1:32 left before the break, but a three by Middlebury's Kira Waldman and a jumper in the waning seconds by Caveney narrowed the gap to single digits (36-27) through two quarters of play.
Shinkus put the margin back to double figures for the hosts on the initial possession of the third frame, but the Panthers put together a modest 7-0 run to close the margin to 38-34. Knox and Waldman sandwiched buckets around a three pointer from Huffman. Middlebury stayed in striking distance at the end of the stanza, trailing 50-43 with 10 minutes remaining.
DeSales extended the lead back to double figures (54-44) on a basket by Emma Stanfield less than three minutes into the fourth. The Bulldogs claimed their biggest advantage of the contest at 65-44 in the closing minutes of the 15-point victory.
Caveney led the Panthers with 16 points, while Knox contributed with 11 points. Davis recorded her eighth double-double of the season with 10 points and 10 boards, with Huffman and Waldman each finishing with eight points.
Morgan Birmelin notched a game-high 19 points for the Bulldogs, to go along with eight assists and five steals. Shinkus netted 18 points with eight rebounds and Averi Jordan added 11 points.
Middlebury shot 27.8 percent (15-54) from the floor, while the hosts hits 40.9 percent (27-66).


ICICI Prudential Mutual Fund has declared dividend under dividend option of ICICI Prudential Discovery Fund on the face value of Rs 10 per unit.
The quantum of dividend will be Rs 1 per unit as on record date. The record date for the dividend payout has been fixed as March 16, 2012.